Do you have a poster presentation at ESMO24?

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.

This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.

If you want your poster to be featured on our website, please tag OncoDaily on LinkedIn and X.

Here are some poster presentations from ESMO24:

Zena Haddadin:

“Breaking new ground at ESMO24 with the largest study on GTN using machine learning!

We’re setting new standards in Personalized Medicine, optimizing treatment plans based on unique patient data.

Discover our insights at poster session 785!”

Sara Haddadin:

“Does chemotherapy have benefits for gestational choriocarcinoma?

Our study differentiates gestational from nongestational choriocarcinoma using nomograms for personalized care.

Join the discussion at poster session 784!”

Daniel Michaeli:

“Excited to present our poster on the tumor response of cancer drugs in single-arm FDA approval trials with Elias Mossialos at ESMO24.

Average ORR of 47% with a DoR of 11 months!”

César Serrano García:

“Come to see our GEIS poster on sociodemographic factors influencing awareness of sarcoma patient associations in Spain.

Presenter Pau Mascaró Baselga, VHIO.”

Herbert Loong:

“Check out the poster by MyLiferaft being presented in board 1758P at ESMO24 describing a global cohort of GIST patients and their outcomes on imatinib based on specific mutations and sensitivity. GISTs Sarcomas Sara Rothschild, Denisse Evans et al.”

Aida Piedra:

“Thank you Jarushka Naidoo for awarding our SCLC work with Best poster at ESMO24! You are such an inspiration to me!! We’ll keep working on SCLC! Thank you Marga Majem for making it possible!”

Chadi Hage Chehade:

“Make sure to stop by poster 1580P at ESMO24. In Flatiron Health: we report disparities in NGS testing based on race-ethnicity and socioeconomic status in > 60,000 patients with breast, prostate, lung, colorectal, and pancreatic cancers.”

Daniel Michaeli:

“Our poster on new NSCLC drugs with Aakash Desai at ESMO24

• 56 FDA NSCLC approvals 2000-2022
• Avg. benefit: OS 3 mts, PFS 1.8 mts
• Biomarkers (64%) with shorter dvlp times, greater benefit, and cost-effectiveness.”

More posts featuring ESMO24 on oncodaily.com